A Trial of Endostar in Patients With Carcinoma of the Head and Neck
Status:
Unknown status
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of recombinant human
endostatin（continuously-pumped）combined with chemoradiotherapy in patients with advanced
squamous cell carcinoma of the head and neck. The patients will be randomized to concurrent
radiotherapy (CRT) arm and CRT + Endostar arm. All patients will receive one cycles of
induction chemotherapy, intensity modulated radiation therapy (IMRT) with weekly cisplatin
and 3 cycles of chemotherapy after IMRT. Treatment cycles will be repeated every 21 days for
a maximum of 4 cycles. In CRT + Endostar arm, Endostar will be continuously intravenous
pumped (7.5 mg/m2) for 14 days (d1-d14) during chemotherapy and for 5 days/week (d-5-d-1,
d3-d7, d10-d14, d17-d21) during IMRT.